Tiziana Life Sciences Ltd

As of December 31, 2025, Tiziana Life Sciences Ltd. carries a market capitalization of 162.68M, placing it among publicly traded companies globally. Its enterprise value stands at 159.66M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Tiziana Life Sciences Ltd.'s next confirmed earnings release is scheduled for March 3, 2027.

As of December 31, 2025, Tiziana Life Sciences Ltd. has 120.51M shares outstanding.

These figures are as of December 31, 2025.

As of December 31, 2025, Tiziana Life Sciences Ltd. maintains a current ratio of 0.76, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2025.

These figures are as of the close on October 22, 2026. The 50-day moving average sits at 0.90, while the 200-day moving average is 1.06.

As of December 31, 2025, Tiziana Life Sciences Ltd. holds 3.41M in cash and equivalents against 388,101.60 in total debt, resulting in a net debt position of -3.41M. Total book value stands at 44,257.20, with working capital of -2.26M providing operational flexibility.

Tiziana Life Sciences Ltd.'s most recent stock split took place on July 31, 2020 with a 2:5 split ratio.